Plusultra pharma
Plusultra pharma GmbH is a Düsseldorf-based orphan drug subsidiary of Japan's Nobelpharma Group that markets Hyftor 2 mg/g Gel (Sirolimus), an EMA-approved prescription topical treatment for facial angiofibroma in tuberous sclerosis complex, distributed in Germany, France, and Italy.
- Company typePrivate
- Founded2020
- HeadquartersDüsseldorf, Germany
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Plusultra pharma does
Plusultra pharma GmbH is a privately held, Düsseldorf-based pharmaceutical company established in 2020 as the European operating subsidiary of Japan's Nobelpharma Co., Ltd. (founded 2003). The company develops and commercializes prescription pharmaceuticals for unmet medical needs, with an exclusive focus on orphan drugs and rare disease therapeutics — a niche it inherits from its parent group, which deliberately pursues "critical but neglected" products that larger pharmaceutical companies have not addressed. Its sole commercial product is Hyftor 2 mg/g Gel (Sirolimus), a topical gel formulation that received EMA marketing authorization on May 15, 2023, along with Orphan Drug Status, for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and pediatric patients aged six and older.
The business model is conventional prescription pharmaceutical sales: Plusultra pharma holds the marketing authorization and captures revenue from product sales, while leveraging third-party partners for distribution and in-market promotion. In Germany, the home market, PHOENIX Pharma-Einkauf GmbH (Hanau) serves as the wholesale distributor to pharmacies and full-line wholesalers. Following successful price negotiations with the German statutory health insurance body GKV-SV in October 2024, Hyftor became fully reimbursable. In April and May 2025, Plusultra pharma announced a multi-country partnership with InfectoPharm Arzneimittel und Consilium GmbH covering exclusive marketing of Hyftor in France and Italy and a marketing collaboration in Germany, signaling a shift from single-market to multi-market European commercialization.
Plusultra pharma GmbH is a German limited liability company (GmbH) under Japanese parent ownership, with a sister entity, Plusultra pharma UK Ltd. (Oxford), established in 2020. The company does not publish revenue, headcount, or funding data; its financials are consolidated within Nobelpharma Group. Operating geographies at present include Germany, France, and Italy (the latter two via the InfectoPharm partnership), with the UK subsidiary not yet evidenced to have launched products. The company's competitive position rests on regulatory exclusivity from Orphan Drug Status, a niche specialization in neglected indications, and a lean asset-light commercial model built on partner distribution rather than owned sales infrastructure.
Plusultra pharma firmographics
Firmographics- Name
- Plusultra pharma
- Legal name
- Plusultra pharma GmbH
- Website
- https://plusultra-pharma.de
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Plusultra pharma GmbH is a Düsseldorf-based orphan drug subsidiary of Japan's Nobelpharma Group that markets Hyftor 2 mg/g Gel (Sirolimus), an EMA-approved prescription topical treatment for facial angiofibroma in tuberous sclerosis complex, distributed in Germany, France, and Italy.
- Ownership category
- akta.pro rank
Plusultra pharma industry classification
Industry- Product category
- Specialty Pharmaceuticals (Orphan Drugs)
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
Keywords
Where Plusultra pharma is headquartered
LocationHeadquarters
- HQ city
- Düsseldorf
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Plusultra pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Operations, Marketing or Sales, Personnel
Revenue model
- Pharmaceutical Product Sales: Revenue generated from sales of prescription-only pharmaceutical products, specifically Hyftor 2 mg/g Gel. Products are distributed through pharmacy networks via wholesale distribution partners. The company operates in the orphan drugs market segment for rare diseases.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Plusultra pharma product offering
Product offeringCore offering
Plusultra pharma GmbH is a research and development-based pharmaceutical company that develops and markets prescription pharmaceuticals for unmet medical needs, with a particular focus on orphan drugs for rare diseases. Its primary commercial product is Hyftor 2 mg/g Gel (Sirolimus), a topical prescription medication approved by the European Medicines Agency in May 2023 for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and pediatric patients aged six years and older. The company sells exclusively through pharmaceutical wholesale and channel partners that supply pharmacies and healthcare professionals across Germany, France, Italy, and the United Kingdom.
Product overview
Plusultra pharma GmbH is a research and development-based pharmaceutical company that develops pharmaceuticals for unmet medical needs, including orphan drugs, off-label drugs, and treatments for intractable diseases. The company operates as a subsidiary of Nobelpharma Group (headquartered in Tokyo, Japan) with a focus on rare diseases. The primary product is Hyftor 2 mg/g Gel (Sirolimus), a prescription medication approved by EMA in May 2023 for treating facial angiofibroma associated with tuberous sclerosis complex. The company collaborates with distribution partners including PHOENIX Pharma-Einkauf GmbH for German market distribution and InfectoPharm for marketing in Germany, France, and Italy.
Differentiator
Problem solved
Functional benefit
Products and services
- Hyftor 2 mg/g Gel (Sirolimus) Prescription-only topical gel containing sirolimus indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and pediatric patients aged six years and older. Distributed through pharmacies and pharmaceutical wholesalers in Germany and other European markets and reimbursed via GKV-SV in Germany.
Companies that use Plusultra pharma
Customer profileSegments1 record
Ideal customer profiles1 record
Plusultra pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Plusultra pharma partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- InfectoPharm Arzneimittel und Consilium GmbHcorePlusultra pharma and InfectoPharm announced partnership for marketing Hyftor 2 mg/g Gel in Germany. The collaboration leverages InfectoPharm's expertise in pharmaceutical marketing and distribution to expand reach of the orphan drug treatment for tuberous sclerosis complex patients.
- InfectoPharm Arzneimittel und Consilium GmbHcorePlusultra pharma and InfectoPharm signed binding term sheet for exclusive marketing of Hyftor 2 mg/g Gel in France and Italy. InfectoPharm will promote and distribute the product in these two countries, expanding the market for Hyftor 2 mg/g Gel across Europe.
- PHOENIX Pharma-Einkauf GmbHcoreDistribution partner for Hyftor 2 mg/g Gel in Germany. Products distributed through pharmacies and fully stocked wholesalers. Located at Lippestrasse 9a, 63452 Hanau, Germany.
Scale indicators2 records
Recent moves6 records
Expansion highlights4 records
Plusultra pharma competitors and assessment
Company assessmentDirect peers
- BioMarin Pharmaceutical: Global rare-disease biotech with multiple orphan drugs on the market. Comparable as a specialty pharma pure-play targeting small patient populations with high-unmet-need conditions, though operating at a much larger scale.
- Ultragenyx Pharmaceutical: Commercial-stage rare-disease company developing and commercializing treatments for serious rare and ultra-rare genetic diseases. Comparable business model to Plusultra in targeting small orphan populations with regulatory exclusivity.
- Swedish Orphan Biovitrum (Sobi): European-headquartered specialty pharmaceutical company focused exclusively on rare diseases. Directly comparable to Plusultra in mission, customer (rare-disease patients/prescribers), and orphan-drug commercialization model across EU markets.
- Orphan Europe (Recordati Group): Recordati's dedicated rare-disease unit commercializing orphan drugs across Europe. Direct comparable to Plusultra in its European orphan-drug commercialization focus and small-patient-population go-to-market approach.
- Jazz Pharmaceuticals: Specialty pharmaceutical company with a significant orphan and rare-disease franchise across oncology and neurology. Comparable as a specialty pharma operator commercializing niche, high-unmet-need therapeutics through targeted channels.
- Recordati Rare Diseases: Specialty division of Recordati focused on rare and orphan diseases across Europe. Closely mirrors Plusultra's strategy of selling niche, high-unmet-need pharmaceuticals through established European distribution networks.
- HRA Pharma (Perrigo Company): European specialty pharma with a dedicated rare-disease business (HRA Pharma Rare Diseases). Comparable as a focused orphan-drug marketer operating across EU regulatory and reimbursement environments.
- Advanz Pharma: European specialty pharmaceutical company focused on rare diseases, hospital-only medicines and specialty therapeutics. Comparable to Plusultra in its European orphan-drug focus and specialty distribution model.
Broad incumbents
- Novartis: Major incumbent with Afinitor/Votubia (everolimus) approved for TSC-related manifestations including SEGA and renal angiomyolipoma. Direct competitor in the TSC treatment paradigm and a broad orphan/specialty pharma incumbent.
- Alexion / AstraZeneca Rare Disease: Established rare-disease franchise now part of AstraZeneca, offering multiple orphan drugs across EU. Comparable as a broader incumbent in the same specialty/rare-disease category, though with a much wider portfolio and deeper resources.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Plusultra pharma social profiles
Digital presencePlusultra pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Plusultra pharma leadership team
Management profileNumber of profiles
Plusultra pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Plusultra pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Plusultra pharma
What does Plusultra pharma do?
Plusultra pharma GmbH is a research and development-based pharmaceutical company that develops and markets prescription pharmaceuticals for unmet medical needs, with a particular focus on orphan drugs for rare diseases. Its primary commercial product is Hyftor 2 mg/g Gel (Sirolimus), a topical prescription medication approved by the European Medicines Agency in May 2023 for the treatment of facial angiofibroma associated with tuberous sclerosis complex (TSC) in adults and pediatric patients aged six years and older. The company sells exclusively through pharmaceutical wholesale and channel partners that supply pharmacies and healthcare professionals across Germany, France, Italy, and the United Kingdom.
Is Plusultra pharma a public or private company?
Plusultra pharma is a private company. It is classified as corporate owned and is currently operating.
When was Plusultra pharma founded?
Plusultra pharma was founded in 2020. It employs 1 to 10 people.
Where is Plusultra pharma based?
Plusultra pharma is headquartered in Düsseldorf, Germany, in the Europe region.
How does Plusultra pharma make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Plusultra pharma's main competitors?
Direct peers on record are BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Swedish Orphan Biovitrum (Sobi), Orphan Europe (Recordati Group), Jazz Pharmaceuticals, Recordati Rare Diseases, HRA Pharma (Perrigo Company) and Advanz Pharma. Broad incumbents are Novartis and Alexion / AstraZeneca Rare Disease.
Does Plusultra pharma have an API?
No public API is recorded for Plusultra pharma.
What industry is Plusultra pharma in?
Plusultra pharma's product category is Specialty Pharmaceuticals (Orphan Drugs). Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.